Construction and evaluation of a nomogram for predicting survival in patients with lung cancer

Ouyang, Jin; Hu, Zhijian; Tong, Jianlin; Yang, Yong; Wang, Juan; Chen, Xi; Luo, Ting; Yu, Shiqun; Wang, Xin; Huang, Shaoxin

doi:10.18632/aging.203974

Cited by 5 publications

(2 citation statements)

References 49 publications

(40 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the present study, we developed and validated a simple and reliable tool to predict the survival 1-,2-, and Our results suggest that stage tumor is a risk factor for lung cancer OS, which is easy to understand, and that OS is certainly shorter in stage patients than in stage -patients. This result is consistent with previous research results (Ouyang et al 2022).…”

Section: Discussionsupporting

confidence: 94%

Development and validation of a novel nomogram for predicting overall survival of lung cancer patients treated with immune checkpoint inhibitors: A retrospective cohort study in China

Mu,

Pan,

Lei

et al. 2023

Preprint

View full text Add to dashboard Cite

Background The purpose of this study was to establish a simple-to-use nomogram for predicting overall survival (OS) among lung cancer patients treated with immune checkpoint inhibitors (ICIs) based on robust clinicopathological prognostic factors. Materials and Methods A total of 1314 patients with lung cancer who had received ICIs therapy were followed up, and R statistical software was used for statistical analysis. The independent prognostic factors of OS were obtained by Cox regression, The consistency index (C-index) value, calibration curve and decision curve analysis (DCA) are used to evaluate the performance and identification ability of nomogram. Results Nine prognostic factors, including age, tumor node metastasis classification stage (TNM stage), surgery, radiation, Karnofsky performance status (KPS), histology, multidrug Therapy, D-dimer, albumin (ALB) were obtained by variable screening and combining with clinical practice. On this basis, the nomogram was developed to predict lung cancer patients' prognoses with ICIs treatment. Nomogram's C-index was calculated to predict 1-, 2-, and 3-year OS response 0.720(95% CI, 0.667–0.723), 0.742(95% CI, 0.686–0.797), 0.683(95% CI, 0.604–0.763), respectively, in the training cohort (P < 0.001). In the validation cohort, the C-indexes were 0.727 (95% CI, 0.649–0.806), 0.659 (95% CI, 0.562–0.755), and 0.637(95% CI, 0.482–0.792), respectively. DCA demonstrated that the nomogram was beneficial to clinical practice, Using the nomogram, lung cancer patients were categorized into two groups based on their mortality risk. In addition, a dynamic nomogram of the network services calculator was built. Conclusion A predictive nomogram based on commonly available factors could help clinicians screen lung cancer patients who would benefit from ICIs treatment and provide robust personalized prognostication.

show abstract

Section: Discussionsupporting

confidence: 94%

Development and validation of a novel nomogram for predicting overall survival of lung cancer patients treated with immune checkpoint inhibitors: A retrospective cohort study in China

Mu,

Pan,

Lei

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…The present survival analyses based on DSS, DFI and PFI in PDAC were consistent with previous reports ( Fig. 1 ; Table I ) ( 27 , 28 ). Notably, the present results revealed that patients with SLC20A1 high showed a poorer prognosis than patients with SLC20A1 low at tumor stage I.…”

Section: Discussionsupporting

confidence: 92%

Co‑expression of SLC20A1 and ALDH1A3 is associated with poor prognosis, and SLC20A1 is required for the survival of ALDH1‑positive pancreatic cancer stem cells

Matsuoka,

Kasai,

Onaga

et al. 2024

Oncol Lett

View full text Add to dashboard Cite

Solute carrier family 20 member 1 (SLC20A1) is a sodium/inorganic phosphate symporter, which has been identified as a prognostic marker in several types of cancer, including pancreatic cancer. However, to the best of our knowledge, the association between SLC20A1 expression and cancer stem cell (CSC) markers, such as aldehyde dehydrogenase 1 (ALDH1), in pancreatic ductal adenocarcinoma (PDAC), and the role of SLC20A1 in PDAC CSCs remains unclear. In the present study, a genomic dataset of primary pancreatic cancer (The Cancer Genome Atlas, Pan-Cancer Atlas) was downloaded and analyzed. Kaplan-Meier analysis and multivariate Cox regression analysis were performed to evaluate the overall survival, disease-specific survival (DSS), disease-free interval (DFI) and progression-free interval (PFI). Subsequently, SLC20A1 small interfering RNA (siRNA) knockdown (KD) was induced in the PANC-1 and MIA-PaCa-2 PDAC cell lines, and in sorted high ALDH1 activity (ALDH1 high ) cells, after which, cell viability, in vitro tumor sphere formation, cell death and caspase-3 activity were examined. The results revealed that patients with high expression of SLC20A1 ( SLC20A1 high ) at tumor stage I had a poor prognosis compared with patients with low expression of SLC20A1 ( SLC20A1 low ) in terms of DSS, DFI and PFI. In addition, patients with high expression of SLC20A1 and ALDH1A3 ( SLC20A1 high ALDH1A3 high ) exhibited poorer clinical outcomes than patients with high expression of SLC20A1 and low expression of ALDH1A3 ( SLC20A1 high ALDH1A3 low ), low expression of SLC20A1 and high expression of ALDH1A3 ( SLC20A1 low ALDH1A3 high ) and SLC20A1 low ALDH1A3 low . SLC20A1 siRNA KD in ALDH1 high cells isolated from PANC-1 and MIA-PaCa-2 cell lines resulted in suppression of in vitro tumorsphere formation, and enhancement of cell death and caspase-3 activity. These results suggested that SLC20A1 was involved in cell survival via the suppression of caspase-3-dependent apoptosis, and contributed to cancer progression and poor clinical outcomes in PDAC. In conclusion, SLC20A1 may be used as a prognostic marker and novel therapeutic target of ALDH1-positive pancreatic CSCs.

show abstract

Construction and validation of a novel prognostic nomogram for predicting overall survival in lung adenocarcinoma patients with different patterns of metastasis

Xiong,

Gu,

Cui

et al. 2023

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

Objective Metastasis of lung cancer is an important factor affecting survival. The present study proposed to establish and verify a nomogram for predicting overall survival (OS) in lung adenocarcinoma (LUAD) patients with different patterns of metastasis. Methods A total of 9727 patients diagnosed with metastatic LUAD patients from 2010 to 2015 were enrolled based on surveillance, epidemiology and end results (SEER) Database and then randomly divided into training and validation cohorts, and 136 patients in our Cancer Center were enrolled as the external validation cohort. Univariate and multivariate analyses were performed to evaluate the prognostic impact on OS. A prognostic nomogram was constructed and evaluated by C-index, calibration curve, decision curve analysis (DCA), and risk stratification system. Results Ultimately, 6809 and 2918 patients diagnosed with metastatic LUAD in the training and validation cohorts were enrolled in the study, respectively. A male sex, a later T and N stage, a larger tumor size, treatment including no surgery, no chemotherapy and no radiotherapy, metastasis sites were found to be independent risk factors in LUAD patients for worse OS, and then incorporated into the nomogram. The frequency of bone metastasis was the highest, and in single site metastasis, the prognosis of liver metastasis was the worst. Two-site metastasis is more common than three-site and four-site metastasis, and co-metastasis eventually leads to a worse survival outcome. The C-index value of nomogram for predicting OS were 0.798, 0.703 and 0.698 in the internal training, validation and external validation cohorts, separately. The calibration curves for the 6-months, 1-year and 2-year showed significant agreement between nomogram models and actual observations. The DCA curves indicated nomogram was more beneficial than the AJCC TNM stage. Patients were further divided into low-risk and high-risk groups according to nomogram predicted scores and developed a survival risk classification system. Conclusions Our prognostic nomogram is expected to be an accurate and individualized clinical predictive tool for predicting OS in LUAD patients with different patterns of metastasis.

show abstract

Construction and evaluation of a nomogram for predicting survival in patients with lung cancer

Cited by 5 publications

References 49 publications

Development and validation of a novel nomogram for predicting overall survival of lung cancer patients treated with immune checkpoint inhibitors: A retrospective cohort study in China

Development and validation of a novel nomogram for predicting overall survival of lung cancer patients treated with immune checkpoint inhibitors: A retrospective cohort study in China

Co‑expression of SLC20A1 and ALDH1A3 is associated with poor prognosis, and SLC20A1 is required for the survival of ALDH1‑positive pancreatic cancer stem cells

Construction and validation of a novel prognostic nomogram for predicting overall survival in lung adenocarcinoma patients with different patterns of metastasis

Contact Info

Product

Resources

About